Clinical trial
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage…
NCT00292227 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00292227 |
|---|---|
| Title | Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease |
| Official title | Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial. |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug, Other |
| Interventions | Rotigotine, Placebo, Moxifloxacin infusion, Placebo infusion |
| Enrollment | 130 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Feb 15, 2006 |
| Last update posted | Oct 27, 2014 |
| Countries | South Africa |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: